PRECISION BIOSCIENCES INC

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

DTIL$9.68-8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Operations

(In thousands, except share and per share amounts)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2026	2025	2026	2025
Revenue	$—	$18	$10,838	$47
Operating expenses
Research and development	12,394	12,768	25,504	26,356
General and administrative	6,767	9,127	13,570	17,680
Total operating expenses	19,161	21,895	39,074	44,036
Operating loss	(19,161)	(21,877)	(28,236)	(43,989)
Other (expense) income:
(Loss) gain from equity method investment	—	(665)	—	677
Loss on changes in other fair value adjustments	(244)	(2,464)	(3,195)	(2,415)
(Loss) gain on change in fair value of warrant liability	(13,891)	753	(20,998)	(51)
Interest expense	(300)	(358)	(611)	(712)
Interest income	943	1,116	1,942	2,439
Gain (loss) on disposal of assets	1	(25)	5	(34)
Total other expense	(13,491)	(1,643)	(22,857)	(96)
Net loss	$(32,652)	$(23,520)	$(51,093)	$(44,085)
Net loss per share
Basic	$(1.26)	$(2.13)	$(2.02)	$(4.33)
Diluted	$(1.26)	$(2.13)	$(2.02)	$(4.33)
Weighted-average shares of common stock outstanding
Basic	25,856,628	11,046,401	25,248,912	10,174,193
Diluted	25,856,628	11,046,401	25,248,912	10,174,193

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.